Example collocations logo

Pharmaceutical in sentence

484 examples of Pharmaceutical in a sentence

It's a pharmaceutical product.
And the answer is quite simple: the Chinese define these facilities as chemical facilities, not pharmaceutical facilities, so they don't audit them.
We still can't diagnose CTE in living people, we have no treatments that are going to be coming out of the pharmaceutical industry in the next five years.
This is a pharmaceutical ad.
It's not a real pharmaceutical ad.
So it's exactly the way we get health information and pharmaceutical information, and it just sounds perfect.
A number of pharmaceutical companies were working on it.
And we can also remember how the pharmaceutical companies were willing to pool their knowledge, to share their knowledge, in the face of an emergency, which they hadn't really been for years and years.
What I find really fascinating is that the pharmaceutical industry uses exactly the same kinds of tricks and devices, but slightly more sophisticated versions of them, in order to distort the evidence they give to doctors and patients, and which we use to make vitally important decisions.
Now, not being a drug company, we could do certain things, we had certain flexibilities, that I respect that a pharmaceutical industry doesn't have.
Well, they probably would keep this a secret until they turn the prototype drug into an active pharmaceutical substance.
It's the information that we most need from pharmaceutical companies, the information on how these early prototype drugs might work.
That was at a pharmaceutical distributor, so they told us not to use that video.
We have pharmaceutical companies that are constantly trying to expand the indications, expand the number of people who are eligible for a given treatment, because that obviously helps their bottom line.
The pharmaceutical industry is in deep trouble.
First of all, there aren't a lot of big inventions in the pipeline, and this is a big problem for human health, and the pharmaceutical industry has got a bigger problem, that they're about to fall off something called the patent cliff.
The pharmaceutical industry needs to place assets in a commons.
What we saw very quickly is the world of both medical research, but also developing drugs and treatments, is dominated by, as you would expect, large organizations, but in a new field, sometimes large organizations really have trouble getting out of their own way, and sometimes they can't ask the right questions, and there is an enormous gap that's just gotten larger between academic research on the one hand and pharmaceutical companies and biotechs that are responsible for delivering all of our drugs and many of our treatments, and so we knew that to really accelerate cures and therapies, we were going to have to address this with two things: new technologies and also a new research model.
We are all different, and a disease that I might have, if I had Alzheimer's disease or Parkinson's disease, it probably would affect me differently than if one of you had that disease, and if we both had Parkinson's disease, and we took the same medication, but we had different genetic makeup, we probably would have a different result, and it could well be that a drug that worked wonderfully for me was actually ineffective for you, and similarly, it could be that a drug that is harmful for you is safe for me, and, you know, this seems totally obvious, but unfortunately it is not the way that the pharmaceutical industry has been developing drugs because, until now, it hasn't had the tools.
The patents on those drugs were held by a number of Western pharmaceutical companies that were not necessarily willing to make those patents available.
There were countries that did not recognize pharmaceutical product patents, such as India, and Indian pharmaceutical companies started to produce so-called generic versions, low-cost copies of antiretroviral medicines, and make them available in the developing world, and within a year the price had come down from 10,000 dollars per patient per year to 350 dollars per patient per year, and today that same triple pill cocktail is available for 60 dollars per patient per year, and of course that started to have an enormous effect on the number of people who could afford access to those medicines.
It relies on the willingness of pharmaceutical companies to license their patents and make them available for others to use.
The company itself, Oxitec, we've been working for the last 10 years, very much on a sort of similar development pathway that you'd get with a pharmaceutical company.
If you work for a funding agency or pharmaceutical company, I challenge you to hold your employers to fund research that is ethically sound.
Now that same kind of software could destroy an oil refinery or a pharmaceutical factory or a semiconductor plant.
And somebody like Dr. Victoria Hale, who started the world's first nonprofit pharmaceutical company, and whose first drug will be fighting visceral leishmaniasis, also known as black fever.
Getting it wrong, and the pharmaceutical industry can still do very well for its shareholders but nothing improves for the people with bruised shins.
So the pharmaceutical industry, which I am personally very interested in because I've actually had the fortune to study it in quite some depth, is wonderful to be asking this question about the revolutionary versus non-revolutionary bits, because each and every medicine can actually be divided up on whether it really is revolutionary or incremental.
This could really revolutionize and be a game changer for not only the pharmaceutical industry, but a whole host of different industries, including the cosmetics industry.
We talked to pharmaceutical companies.
Next